Amplia Therapeutics reports new pancreatic cancer data as narmafotinib advances in four trials

Amplia Therapeutics has reported new data from its pancreatic cancer trial suggesting its lead drug narmafotinib may work independently of KRAS gene mutations, according to The Sydney Morning Herald. The ACCENT trial showed a 36% response rate and 11.1-month median overall survival, with two patients surviving two years.

Amplia's ACCENT Trial Data and Narmafotinib's Mechanism

Amplia Therapeutics is an Australian biotech developing narmafotinib, a Focal Adhesion Kinase (FAK) inhibitor, across pancreatic, ovarian and lung cancer trials. The ACCENT trial evaluates narmafotinib combined with standard chemotherapy in newly diagnosed metastatic pancreatic cancer patients. Previously reported data showed a 36% response rate, 11.1-month median overall survival and a 7.8% complete response rate. The latest findings suggest the treatment may have staying power, with two patients now having reached two years in the study and a third still receiving treatment after 19 months.

KRAS gene mutations are found in more than 90% of pancreatic cancers, making them a major focus for drug developers. The US Food and Drug Administration recently approved a new KRAS-targeting drug that showed a significant survival benefit. Amplia's data suggest narmafotinib could work alongside KRAS drugs, potentially making it effective in a broader patient population or in combination treatments.

Amplia Therapeutics chief medical officer Dr Jason Lickliter said: "It is exciting to be moving forward with these trials as the company builds on the positive clinical data from the ACCENT trial and the promising preclinical data underpinning the PRROSE and Lilly combination studies."

Amplia's Earlier Pancreatic Cancer Trial Milestones

In September 2026, Amplia Therapeutics reported data from its ACCENT study showing 5 complete responses out of 64 patients with narmafotinib plus chemotherapy, according to Yahoo. In August 2026, the company presented ACCENT trial data at the AACR Annual Meeting showing 11.1 months median overall survival, 36% overall response rate and 70% disease control rate in metastatic pancreatic cancer patients, according to AInvest. In July 2026, Amplia initiated a Phase 2b clinical study for narmafotinib in combination with chemotherapy for advanced pancreatic cancer, following mature ACCENT trial data, according to Kalkine.

How Amplia's Data Compares With Sector Peers

GSK announced on October 18, 2026 that its Ris-Rez achieved a 61% response rate at 8 mg/kg in an early-stage lung cancer trial, with Phase Ib findings supporting a higher dose for the ongoing global phase III EMBOLD SCLC-301 trial, according to The future of trading. Amphista Therapeutics announced on October 12, 2026 the first patient dosed in its BRAMLIE Phase 1 trial for AMX-883 in acute myeloid leukemia and high-risk MDS, targeting about 54 patients, according to News-Medical.

Amplia's Next Steps for Narmafotinib Trials

Amplia expects ethics approval imminently for ACCENT-Mini, which will evaluate a daily dosing regimen of narmafotinib plus chemotherapy at three Australian sites, with safety and pharmacokinetic data anticipated in the first half of 2027. The PRROSE ovarian cancer trial, run in collaboration with the Australia New Zealand Gynaecological Oncology Group, is nearing recruitment of 26 patients across Australia and New Zealand. Amplia is also preparing a separate update on its trial combining narmafotinib with Eli Lilly's experimental KRAS G12C inhibitor olomorasib in advanced non-small cell lung cancer.